Horizons Ventures

Amber Salzman, Ph.D., CEO of Epic Bio, Recognized by Endpoints News as One of the Most Influential Women in Biopharma R&D

Retrieved on: 
Wednesday, December 7, 2022
Research, Women, Genetics, Biotechnology, Health, Consumer, Pharmaceutical, General Health, Science, Gene expression, Biotechnology, Therapy, AAV, Culture, A1AD, GEMS, Woman, DCAS, Amber, Stop, Patient, Epic, DNA, Research, Disease, ALD, News, FSHD, Horizons Ventures, CRISPR, DNA-binding protein, Facioscapulohumeral muscular dystrophy, Pharmaceutical industry, Vaccine

She will additionally be featured in Endpoints Women in Biopharma 2022 special report.

Key Points: 
  • She will additionally be featured in Endpoints Women in Biopharma 2022 special report.
  • I am honored to be selected as one of Endpoints influential women blazing trails in biopharma, but my success would not have been possible without the Epic Bio team and the many people who supported and mentored me through my journey.
  • In addition, we have built a culture of diversity and inclusivity at Epic that enhances our ability to innovate.
  • Each year, Endpoints News selects 20 women in biotech to be honored as trailblazers in biopharma R&D.

Epic Bio to Participate in the BMO Virtual Spotlight Series

Retrieved on: 
Tuesday, November 15, 2022
Health, Genetics, General Health, Research, Science, Pharmaceutical, Biotechnology, AAV, GEMS, Gene expression, Biotechnology, Engineering, Bio, DNA, DCAS, Research, Horizons Ventures, CRISPR, DNA-binding protein, FSHD, A1AD, Facioscapulohumeral muscular dystrophy, Vaccine

Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas protein, today announced that the company will be participating in the BMO Virtual Spotlight Series: Epigenome Editing, on November 21, 2022.

Key Points: 
  • Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas protein, today announced that the company will be participating in the BMO Virtual Spotlight Series: Epigenome Editing, on November 21, 2022.
  • Amber Salzman, Ph.D., chief executive officer, and Dan Hart, Ph.D., head of technology development, are scheduled to participate in a fireside chat from 11:00 11:25 am ET.
  • Epic Bio is a leading epigenome engineering company leveraging the power of CRISPR without cutting DNA.
  • Epic Bio has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypocholesterolemia (HeFH), as well as other indications.

Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases

Retrieved on: 
Tuesday, November 8, 2022
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Erythropoietin, B cell, Harvard University, Felicis Ventures, Proteomics, Myotonic dystrophy, Engineering, FDA, DeepMind, Horizon, Foundation for the National Institutes of Health, VC, University of California, Berkeley, Horizons Ventures, Insulin, Growth hormone, Systems biology, Venture capital, Series A round, Impossible Foods, Regenerative medicine, National Institute, Biomarker, Drug discovery, Intersection, California Institute for Regenerative Medicine, Stanford University, Regeneration, Doctor of Philosophy, Ageing, Investment, Protein, Protein engineering, Biology, Degenerative disease, California Institute for Quantitative Biosciences, Therapy, SVP, Compound, Siri, Map, Mubadala Investment Company, Pharmaceutical industry, Vaccine, Spotify

The new funding will power the expansion of Juvenas drug discovery platform and advance the companys biologics pipeline targeting chronic and age-related diseases.

Key Points: 
  • The new funding will power the expansion of Juvenas drug discovery platform and advance the companys biologics pipeline targeting chronic and age-related diseases.
  • Secreted proteins are a proven class of biologics with tremendous therapeutic potential, as they regulate tissue repair and regeneration, organ development, and immune response to disease.
  • These limitations have constrained biopharmas approach to studying the role of secreted proteins only as drug targets or biomarkers, rather than drug agents themselves.
  • Juvena Therapeutics is a biotech company accelerating the development of therapeutics by unlocking the therapeutic potential of secreted proteins.

Epic Bio Presents First Data Supporting Persistent and Tunable Gene Activation Using Transient Delivery

Retrieved on: 
Monday, October 31, 2022
Research, Hospitals, Genetics, Clinical Trials, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Biotechnology, AAV, Horizons Ventures, Bio, FSHD, Gene expression, Research, GEMS, Facioscapulohumeral muscular dystrophy, Biological engineering, Risk, Asilomar International Conference on Climate Intervention Technologies, CRISPR, DCAS, Engineering, A1AD, Technology, Gene, DNA-binding protein, DNA, Conference, Vaccine

Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, presented multiple datasets demonstrating persistent gene activation at the 6th International Conference on Epigenetics and Bioengineering, on October 29, 2022, in Houston, Texas.

Key Points: 
  • Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, presented multiple datasets demonstrating persistent gene activation at the 6th International Conference on Epigenetics and Bioengineering, on October 29, 2022, in Houston, Texas.
  • We are excited to present our data as it supports the potential of a permanent cure for diseases needing tunable upregulation of protein.
  • Looking at the data, weve shown our newly designed activator was capable of delivering persistent gene activation to our target genes of interest; thus, allowing us to tune gene expression.
  • Epic Bio is a leading epigenome engineering company, leveraging the power of CRISPR without cutting DNA.

Epic Bio to Participate in the 6th International Conference on Epigenetics and Bioengineering

Retrieved on: 
Tuesday, October 25, 2022
Health, Genetics, Health Technology, Other Health, General Health, Biotechnology, Gene expression, LinkedIn, Bio, FSHD, A1AD, Conference, Biological engineering, Biotechnology, Twitter, Research, International Conference on Green Chemistry, GEMS, DNA-binding protein, AAV, DCAS, CRISPR, Horizons Ventures, DNA, Facioscapulohumeral muscular dystrophy, Vaccine

Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced its participation at the 6th International Conference on Epigenetics and Bioengineering, held in Houston, Texas, taking place October 27 29, 2022.

Key Points: 
  • Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced its participation at the 6th International Conference on Epigenetics and Bioengineering, held in Houston, Texas, taking place October 27 29, 2022.
  • Epic Bio is a leading epigenetic engineering company, leveraging the power of CRISPR without cutting DNA.
  • The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies.
  • Epic Bio has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypocholesterolemia (HeFH), as well as other indications.

Epic Bio Presents Proprietary Gene Expression Modulation System (GEMS) Demonstrating Precise Engineering of DUX4 Gene in Facioscapulohumeral Muscular Dystrophy

Retrieved on: 
Thursday, October 13, 2022
Health, Genetics, Health Technology, Clinical Trials, Pharmaceutical, Biotechnology, Gene expression, LinkedIn, Bio, FSHD, Movement, A1AD, IND, Solebury Township, Bucks County, Pennsylvania, DUX4, Biotechnology, Patient, Depression, RNA, Twitter, Tissue, Research, GEMS, DNA-binding protein, AAV, DCAS, Cas9, Face, CRISPR, Horizons Ventures, Scapula, Anxiety, DNA, Chronic pain, Elective surgery, Facioscapulohumeral muscular dystrophy, FDA, Engineering, Muscular dystrophy, Vaccine

I am excited by the data we will present today on Facioscapulohumeral Muscular Dystrophy (FSHD), the second most prevalent form of muscular dystrophy.

Key Points: 
  • I am excited by the data we will present today on Facioscapulohumeral Muscular Dystrophy (FSHD), the second most prevalent form of muscular dystrophy.
  • Notably, our in vitro results demonstrate the utility of our dCas to suppress DUX4 expression by up to 95%.
  • Facioscapulohumeral Muscular Dystrophy is estimated to be the second most common muscular dystrophy, affecting 1 in 8,000 patients1,2.
  • The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies.

Epic Bio to Participate in the Solebury / BMO Fall Private Company Showcase

Retrieved on: 
Thursday, October 6, 2022
Health, Stem Cells, Genetics, Other Science, Research, Science, Biotechnology, Gene expression, LinkedIn, Bio, Interest, FSHD, A1AD, Solebury Township, Bucks County, Pennsylvania, Biotechnology, Research, Twitter, GEMS, Company, AAV, BMO Capital Markets, CRISPR, Horizons Ventures, DNA, Facioscapulohumeral muscular dystrophy, Vaccine

Epic Bio , a biotechnology company developing therapies to modulate gene expression using the compact, non-cutting dCasMINI protein, today announced that the company will be participating in the Solebury / BMO Fall Private Company Showcase, taking place Thursday, October 13, 2022, in New York.

Key Points: 
  • Epic Bio , a biotechnology company developing therapies to modulate gene expression using the compact, non-cutting dCasMINI protein, today announced that the company will be participating in the Solebury / BMO Fall Private Company Showcase, taking place Thursday, October 13, 2022, in New York.
  • The event is co-hosted by BMO Capital Markets and Goodwin Law.
  • Chief Executive Officer, Amber Salzman, Ph.D. is scheduled to present on October 13 at 2:40 pm ET.
  • Epic Bio is a leading epigenetic engineering company, leveraging the power of CRISPR without cutting DNA.

Kneron Closes B Round at $48 Million

Retrieved on: 
Wednesday, October 5, 2022
SAN, ADATA, Sequoia, City, Telecommunication, MIH, SMAX, Align Technology, Hanwha Techwin, Delta Electronics, AI, Foxconn, CEO, IP, Series, Horizons Ventures, Ali Baba, Solution, TDV, Satellite navigation device, Quanta, Garmin, Qualcomm

SAN DIEGO, Oct. 5, 2022 /PRNewswire/ -- Leading full-stack edge AI company Kneron today announces new series B funding of $48 million led by Horizons Ventures.

Key Points: 
  • SAN DIEGO, Oct. 5, 2022 /PRNewswire/ -- Leading full-stack edge AI company Kneron today announces new series B funding of $48 million led by Horizons Ventures.
  • Albert Liu, founder and CEO of Kneron, says: "We are excited to work our new strategic investors in the advancement of core smart city infrastructures.
  • Over the past year, Kneron saw significant new customer wins spanning multiple verticals including smart vehicles, smart homes and smart cities.
  • To date, Kneron has raised over $140 million, backed by Horizons Ventures , Alibaba , Qualcomm , Sequoia , Foxconn , Circle Investment, and more.

Kneron Closes B Round at $48 Million

Retrieved on: 
Wednesday, October 5, 2022
SAN, ADATA, Sequoia, City, Telecommunication, MIH, SMAX, Align Technology, Hanwha Techwin, Delta Electronics, AI, Foxconn, CEO, IP, Series, Horizons Ventures, Ali Baba, Solution, TDV, Satellite navigation device, Quanta, Garmin, Qualcomm

SAN DIEGO, Oct. 5, 2022 /PRNewswire/ -- Leading full-stack edge AI company Kneron today announces new series B funding of $48 million led by Horizons Ventures.

Key Points: 
  • SAN DIEGO, Oct. 5, 2022 /PRNewswire/ -- Leading full-stack edge AI company Kneron today announces new series B funding of $48 million led by Horizons Ventures.
  • Albert Liu, founder and CEO of Kneron, says: "We are excited to work our new strategic investors in the advancement of core smart city infrastructures.
  • Over the past year, Kneron saw significant new customer wins spanning multiple verticals including smart vehicles, smart homes and smart cities.
  • To date, Kneron has raised over $140 million, backed by Horizons Ventures , Alibaba , Qualcomm , Sequoia , Foxconn , Circle Investment, and more.

Impossible Foods Introduces Impossible™ Bowls — New Plant-Based Meals in the Frozen Aisle

Retrieved on: 
Friday, September 2, 2022
Retail, Other Consumer, Consumer, Women, Supermarket, Men, Food, Beverage, Howard Hughes Medical Institute, Plant, CEO, Global Investors Summit, Viking Global Investors, Food science, Hope, Fusilli, Impossible, Burrito, UBS, Multimedia, French mother sauces, Cholesterol, Water, Animal, Classic, Pea, Map, Temasek, Khosla Ventures, Horizons Ventures, Chili mac, Stanford University, Meat, GV (company), Biochemistry, Open Philanthropy (organization), Impossible Foods, Fast food, Baking, Sales

California-based Impossible Foods, the fastest-growing plant-based meat company in the U.S., launched its latest food concept in the frozen aisle this week with a new lineup of single-serve frozen entrees: Impossible Bowls delicious plant-based meals ready in minutes.

Key Points: 
  • California-based Impossible Foods, the fastest-growing plant-based meat company in the U.S., launched its latest food concept in the frozen aisle this week with a new lineup of single-serve frozen entrees: Impossible Bowls delicious plant-based meals ready in minutes.
  • Teriyaki Impossible Chicken: Seasoned Impossible Chicken, juicy diced pineapple and peas & carrots tossed in a tangy teriyaki glaze, served over white rice.
  • Chili Mac with Impossible Pork: Classic elbow macaroni tossed with Impossible Pork and a hearty chili-style sauce.
  • Earlier this year, Impossible also introduced frozen Impossible Sausage Patties and Impossible Wild Nuggies in February 2022, followed shortly by Impossible Sausage Links in March 2022.